Drug Profile
Research programme: metabolite replacement therapeutics - Comet Therapeutics
Alternative Names: Acetyl-4’-phosphopantetheine; P-PantSAc; TM-1803Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator TIRCON
- Developer Comet Therapeutics; TIRCON; University Medical Center Groningen
- Class Neuroprotectants
- Mechanism of Action Phosphopantothenate replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pantothenate kinase-associated neurodegeneration
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Pantothenate Kinase Associated Neurodegeneration in Netherlands
- 28 Oct 2021 No recent reports of development identified for preclinical development in Pantothenate Kinase Associated Neurodegeneration in USA
- 21 Sep 2021 Comet Therapeutics has been acquired by VectivBio